ArticleBreast cancer research : BCR2026
The absence of B7-H4 inhibits PD-L1 expression by driving a methylation of PD-L1 promoter in breast cancer cells.
Article in Breast cancer research : BCR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A study on the mechanism of action of B7H4 in HER2-positive gastric cancer and its sensitivity to trastuzumab therapy.Translational cancer research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The expression of B7-H4, a co-inhibitory molecule highly detected in cancer cells, serves as an important prognostic marker and therapeutic target in breast cancer. B7-H4 has been shown to modulate the malignancy of breast cancer cells through affecting cell stemness and the epithelial-mesenchymal transition (EMT). However, whether B7-H4 influences the expression of other immunoregulatory molecules, and how this crosstalk contributes to the clinicopathological features of breast cancer remain controversial. Although the majority of the tumors are positive for B7-H4 and negative for PD-L1, we noticed a portion of breast tumor cells (4.3–18.8%) showing co-expression of two molecules. Besides, there is an overall positive correlation in the expression of B7-H4 and PD-L1 in breast cancer. Mechanistically, B7-H4 promotes the transcription of PD-L1 via downregulating the DNA methyltransferase 1 (DNMT1)-mediated methylation in cg19724470 and cg15837913 CpG loci in the promoter of PD-L1. Moreover, the expression of B7-H4 is negatively associated with the methylation levels of these two loci in a breast cancer cohort in the TCGA database, and is necessary for interferon-γ (IFN-γ)-induced PD-L1 expression in breast cancer cells. Pharmacological inhibition of DNMT1 improves IFN-γ responsiveness in breast cancer cells. Functionally, individuals with co-expression of B7-H4 and PD-L1 present higher abundance of CD8A, granzyme B (GZMB) and perforin 1 (PRF1) than those without co-expression in tumor tissues, indicating increased T cell infiltration in these patients. Consistently, the co-expression of these two molecules is also associated with improved disease-free survival in breast cancer patients. Overall, our study unveils a mechanistic link between B7-H4 and PD-L1 expression through DNA methylation-mediated epigenetic regulation in breast cancer, and indicates that epigenetic therapy holds potential in remodeling the immune landscape and overcoming treatment resistance in breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.